Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06480605 in Moderate to Severe Ulcerative Colitis
CTR20210186Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of afimkibart in autoimmune colitis, sponsored by Pfizer. Started Mar 2021; status: completed.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20210186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210186.